Terms: = Thyroid cancer AND EML4, ENSG00000143924, 27436
31 results:
1. Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland.
Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J
Oncotarget; 2024 Feb; 15():106-116. PubMed ID: 38329731
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary thyroid cancer.
Wu S; Liu Y; Li K; Liang Z; Zeng X
J Mol Diagn; 2023 Aug; 25(8):569-582. PubMed ID: 37236546
[TBL] [Abstract] [Full Text] [Related]
3. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma.
Wang T; Du G; Niu M; Liu R
BMC Pulm Med; 2023 Feb; 23(1):60. PubMed ID: 36755262
[TBL] [Abstract] [Full Text] [Related]
4. [Comparison of the methods for detecting NTRK gene fusion variations in papillary thyroid carcinoma].
Jiang YY; Chen H; Xu BL; Wang S
Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):726-732. PubMed ID: 35922162
[No Abstract] [Full Text] [Related]
5. Identification of fusions with potential clinical significance in melanoma.
Moran JMT; Le LP; Nardi V; Golas J; Farahani AA; Signorelli S; Onozato ML; Foreman RK; Duncan LM; Lawrence DP; Lennerz JK; Dias-Santagata D; Hoang MP
Mod Pathol; 2022 Dec; 35(12):1837-1847. PubMed ID: 35871080
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological and Molecular Features of Secondary cancer (Metastasis) to the thyroid and Advances in Management.
Nguyen M; He G; Lam AK
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328664
[TBL] [Abstract] [Full Text] [Related]
7. Targeting eml4-ALK gene fusion variant 3 in thyroid cancer.
Aydemirli MD; van Eendenburg JDH; van Wezel T; Oosting J; Corver WE; Kapiteijn E; Morreau H
Endocr Relat Cancer; 2021 May; 28(6):377-389. PubMed ID: 33878728
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
[TBL] [Abstract] [Full Text] [Related]
9. Genetic Alterations in Pediatric thyroid cancer Using a Comprehensive Childhood cancer Gene Panel.
Alzahrani AS; Alswailem M; Alswailem AA; Al-Hindi H; Goljan E; Alsudairy N; Abouelhoda M
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32556222
[TBL] [Abstract] [Full Text] [Related]
10.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
11. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
Chu YH; Dias-Santagata D; Farahani AA; Boyraz B; Faquin WC; Nosé V; Sadow PM
Mod Pathol; 2020 Nov; 33(11):2186-2197. PubMed ID: 32457407
[TBL] [Abstract] [Full Text] [Related]
12. Characterization of thyroid cancer driven by known and novel ALK fusions.
Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI
Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879
[TBL] [Abstract] [Full Text] [Related]
13. Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.
van der Tuin K; Ventayol Garcia M; Corver WE; Khalifa MN; Ruano Neto D; Corssmit EPM; Hes FJ; Links TP; Smit JWA; Plantinga TS; Kapiteijn E; van Wezel T; Morreau H
Eur J Endocrinol; 2019 Apr; 180(4):235-241. PubMed ID: 30668525
[TBL] [Abstract] [Full Text] [Related]
14. Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma.
Pfeifer A; Rusinek D; Żebracka-Gala J; Czarniecka A; Chmielik E; Zembala-Nożyńska E; Wojtaś B; Gielniewski B; Szpak-Ulczok S; Oczko-Wojciechowska M; Krajewska J; Polańska J; Jarząb B
Genes Chromosomes Cancer; 2019 Aug; 58(8):558-566. PubMed ID: 30664823
[TBL] [Abstract] [Full Text] [Related]
15. Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas.
Matsubara D; Soda M; Yoshimoto T; Amano Y; Sakuma Y; Yamato A; Ueno T; Kojima S; Shibano T; Hosono Y; Kawazu M; Yamashita Y; Endo S; Hagiwara K; Fukayama M; Takahashi T; Mano H; Niki T
Cancer Sci; 2017 Sep; 108(9):1888-1896. PubMed ID: 28677170
[TBL] [Abstract] [Full Text] [Related]
16. Clear Cell Change in thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies.
Cipriani NA; Agarwal S; Dias-Santagata D; Faquin WC; Sadow PM
Thyroid; 2017 Jun; 27(6):819-824. PubMed ID: 28293986
[TBL] [Abstract] [Full Text] [Related]
17. The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking.
Skov BG; Clementsen P; Larsen KR; Sørensen JB; Mellemgaard A
Histopathology; 2017 May; 70(6):889-895. PubMed ID: 27943404
[TBL] [Abstract] [Full Text] [Related]
18. thyroid metastasis from lung adenocarcinoma with eml4-ALK rearrangement.
Kawamoto H; Kaneko Y; Ryu K; Kuwano K
BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27872133
[TBL] [Abstract] [Full Text] [Related]
19. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary thyroid cancer.
Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
[TBL] [Abstract] [Full Text] [Related]
20. Primary pulmonary adenoid cystic carcinoma: clinicopathological analyses of 12 cases.
Qing S; Zhou K; Liu X; Li X; Deng F; Ma Y
Int J Clin Exp Pathol; 2015; 8(6):7619-26. PubMed ID: 26261681
[TBL] [Abstract] [Full Text] [Related]
[Next]
